Thus far, several c-kit inhibitors such as Imatinib and Sunitinib have been approved by FDA to the treatment of leukemia, renal cancer cell, and gastrointestinal stromal tumors [26]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.